GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2010

Charles River to Offer Knockout Rat Models through Deal with Transposagen

  • Charles River Laboratories entered into an exclusive, long-term marketing and distribution agreement with Transposagen Biopharmaceuticals covering Transposagen’s p53 and Bcrp TGEM™ knockout rat models and associated downstream services utilizing these models. The companies have also agreed to an R&D collaboration to create new genetically modified rat models.

    With this deal, Charles River will be able to offer knockout rat models to its clients for the first time. These rat models are expected to provide new opportunities to examine the pharmacokinetics, pharmacodynamics, efficacy, and carcinogenicity as well as other potential toxicities of novel therapeutic compounds.

    Transposagen’s showcase TGEM model, the p53 TGEM knockout rat model, is expected to be a valuable tool in oncology research as it is believed that the Tp53 gene (tumor protein 53) is the most commonly mutated gene in human cancers. The p53 TGEM knockout rat model is also the only fully phenotyped p53 knockout rat model commercially available, according to Charles River and Transposagen.

    The Bcrp TGEM knockout rat model lacks the expression of the drug transporter Bcrp gene (breast cancer resistance protein 1, or Abcg2), which plays a role in multidrug resistance in cancer, the uptake of drugs in cells, and fetal protection during pregnancy.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »